Immunopotentiators	NNS	NP	B-KP 0 18	[1]	[18]	CAPITALIZED	allAlpha
activate	VBP	VP	B-KP 19 27	[2]	[8]	LOWERCASE	allAlpha
innate	JJ	NP	I-KP 28 34	[3]	[6]	LOWERCASE	allAlpha
immunity	NN	NP	I-KP 35 43	[4]	[8]	LOWERCASE	allAlpha
directly	RB	OTHER	O 44 52	[5]	[8]	LOWERCASE	allAlpha
(for	FW	OTHER	O 53 57	[6]	[4]	LOWERCASE	ContainSymbol
example,	FW	OTHER	O 58 65	[7]	[8]	LOWERCASE	ContainSymbol
cytokines)	NN	NP	O 67 77	[8]	[10]	LOWERCASE	ContainSymbol
or	CC	OTHER	O 78 80	[9]	[2]	LOWERCASE	allAlpha
through	IN	PP	O 81 88	[10]	[7]	LOWERCASE	allAlpha
pattern-recognition	NN	NP	B-KP 89 108	[11]	[19]	LOWERCASE	ContainSymbol
receptors	NNS	NP	I-KP 109 118	[12]	[9]	LOWERCASE	allAlpha
(PRRs,	VBP	VP	O 119 124	[13]	[6]	LOWERCASE	ContainSymbol
such	JJ	OTHER	O 126 130	[14]	[4]	LOWERCASE	allAlpha
as	IN	OTHER	O 131 133	[15]	[2]	LOWERCASE	allAlpha
those	DT	OTHER	O 134 139	[16]	[5]	LOWERCASE	allAlpha
for	IN	PP	O 140 143	[17]	[3]	LOWERCASE	allAlpha
bacterial	JJ	NP	O 144 153	[18]	[9]	LOWERCASE	allAlpha
components).	NN	NP	O 154 165	[19]	[12]	LOWERCASE	ContainSymbol

The	DT	OTHER	O 167 170	[1]	[3]	CAPITALIZED	allAlpha
Toll-like	JJ	NP	B-KP 171 180	[2]	[9]	CAPITALIZED	ContainSymbol
receptors	NNS	NP	I-KP 181 190	[3]	[9]	LOWERCASE	allAlpha
(TLRs)	NN	NP	O 191 197	[4]	[6]	LOWERCASE	ContainSymbol
are	VBP	VP	O 198 201	[5]	[3]	LOWERCASE	allAlpha
a	DT	OTHER	O 202 203	[6]	[1]	LOWERCASE	allAlpha
family	NN	NP	O 204 210	[7]	[6]	LOWERCASE	allAlpha
of	IN	PP	O 211 213	[8]	[2]	LOWERCASE	allAlpha
PRRs	NNS	NP	B-KP 214 218	[9]	[4]	CAPITALIZED	allAlpha
that	WDT	OTHER	O 219 223	[10]	[4]	LOWERCASE	allAlpha
are	VBP	VP	O 224 227	[11]	[3]	LOWERCASE	allAlpha
an	DT	OTHER	O 228 230	[12]	[2]	LOWERCASE	allAlpha
important	JJ	NP	O 231 240	[13]	[9]	LOWERCASE	allAlpha
link	NN	NP	O 241 245	[14]	[4]	LOWERCASE	allAlpha
between	IN	OTHER	O 246 253	[15]	[7]	LOWERCASE	allAlpha
innate	JJ	OTHER	O 254 260	[16]	[6]	LOWERCASE	allAlpha
and	CC	OTHER	O 261 264	[17]	[3]	LOWERCASE	allAlpha
adaptive	JJ	NP	O 265 273	[18]	[8]	LOWERCASE	allAlpha
immunity.	NN	NP	O 274 282	[19]	[9]	LOWERCASE	ContainSymbol

Some	DT	OTHER	O 284 288	[1]	[4]	CAPITALIZED	allAlpha
studies	NNS	NP	O 289 296	[2]	[7]	LOWERCASE	allAlpha
have	VBP	VP	O 297 301	[3]	[4]	LOWERCASE	allAlpha
shown	VBN	VP	O 302 307	[4]	[5]	LOWERCASE	allAlpha
that	IN	PP	O 308 312	[5]	[4]	LOWERCASE	allAlpha
TLR	NN	NP	B-KP 313 316	[6]	[3]	CAPITALIZED	allAlpha
ligands	NNS	NP	I-KP 317 324	[7]	[7]	LOWERCASE	allAlpha
have	VBP	VP	O 325 329	[8]	[4]	LOWERCASE	allAlpha
adjuvant	JJ	NP	O 330 338	[9]	[8]	LOWERCASE	allAlpha
activity	NN	NP	O 339 347	[10]	[8]	LOWERCASE	allAlpha
and	CC	OTHER	O 348 351	[11]	[3]	LOWERCASE	allAlpha
enhance	VBP	VP	O 352 359	[12]	[7]	LOWERCASE	allAlpha
antigen-specific	JJ	NP	O 360 376	[13]	[16]	LOWERCASE	ContainSymbol
antibody	NN	NP	O 377 385	[14]	[8]	LOWERCASE	allAlpha
and	CC	OTHER	O 386 389	[15]	[3]	LOWERCASE	allAlpha
cell-mediated	JJ	NP	O 390 403	[16]	[13]	LOWERCASE	ContainSymbol
immune	JJ	NP	O 404 410	[17]	[6]	LOWERCASE	allAlpha
responses,	NN	NP	O 411 420	[18]	[10]	LOWERCASE	ContainSymbol
especially	RB	OTHER	O 422 432	[19]	[10]	LOWERCASE	allAlpha
when	WRB	OTHER	O 433 437	[20]	[4]	LOWERCASE	allAlpha
they	PRP	OTHER	O 438 442	[21]	[4]	LOWERCASE	allAlpha
are	VBP	VP	O 443 446	[22]	[3]	LOWERCASE	allAlpha
combined	VBN	VP	O 447 455	[23]	[8]	LOWERCASE	allAlpha
with	IN	PP	O 456 460	[24]	[4]	LOWERCASE	allAlpha
delivery	NN	NP	O 461 469	[25]	[8]	LOWERCASE	allAlpha
systems	NNS	NP	O 470 477	[26]	[7]	LOWERCASE	allAlpha
that	WDT	PP	O 478 482	[27]	[4]	LOWERCASE	allAlpha
promote	VBP	VP	O 483 490	[28]	[7]	LOWERCASE	allAlpha
their	PRP$	OTHER	O 491 496	[29]	[5]	LOWERCASE	allAlpha
uptake	NN	NP	O 497 503	[30]	[6]	LOWERCASE	allAlpha
and	CC	OTHER	O 504 507	[31]	[3]	LOWERCASE	allAlpha
delivery	NN	NP	O 508 516	[32]	[8]	LOWERCASE	allAlpha
into	IN	PP	O 517 521	[33]	[4]	LOWERCASE	allAlpha
antigen-presenting	JJ	NP	B-KP 522 540	[34]	[18]	LOWERCASE	ContainSymbol
cells	NNS	NP	I-KP 541 546	[35]	[5]	LOWERCASE	allAlpha
[22–24].	CD	OTHER	O 547 554	[36]	[8]	LOWERCASE	ContainSymbol

For	IN	PP	O 556 559	[1]	[3]	CAPITALIZED	allAlpha
clinical	JJ	NP	B-KP 560 568	[2]	[8]	LOWERCASE	allAlpha
studies,	NN	NP	I-KP 569 576	[3]	[8]	LOWERCASE	ContainSymbol
TLR9	NN	NP	B-KP 578 582	[4]	[4]	CAPITALIZED	ContainSymbol
is	VBZ	VP	O 583 585	[5]	[2]	LOWERCASE	allAlpha
generally	RB	OTHER	O 586 595	[6]	[9]	LOWERCASE	allAlpha
stimulated	VBN	VP	B-KP 596 606	[7]	[10]	LOWERCASE	allAlpha
with	IN	PP	O 607 611	[8]	[4]	LOWERCASE	allAlpha
synthetic	JJ	NP	B-KP 612 621	[9]	[9]	LOWERCASE	allAlpha
oligodeoxynucleotides	NNS	NP	I-KP 622 643	[10]	[21]	LOWERCASE	allAlpha
containing	VBG	VP	O 644 654	[11]	[10]	LOWERCASE	allAlpha
one	CD	OTHER	O 655 658	[12]	[3]	LOWERCASE	allAlpha
or	CC	OTHER	O 659 661	[13]	[2]	LOWERCASE	allAlpha
more	JJR	OTHER	O 662 666	[14]	[4]	LOWERCASE	allAlpha
unmethylated	JJ	NP	B-KP 667 679	[15]	[12]	LOWERCASE	allAlpha
CpG	NN	NP	I-KP 680 683	[16]	[3]	CAPITALIZED	allAlpha
dinucleotides.	NN	NP	I-KP 684 697	[17]	[14]	LOWERCASE	ContainSymbol

In	FW	OTHER	O 699 701	[1]	[2]	CAPITALIZED	allAlpha
humans,	FW	OTHER	O 702 708	[2]	[7]	LOWERCASE	ContainSymbol
CpG	NN	NP	B-KP 710 713	[3]	[3]	CAPITALIZED	allAlpha
has	VBZ	VP	O 714 717	[4]	[3]	LOWERCASE	allAlpha
been	VBN	VP	O 718 722	[5]	[4]	LOWERCASE	allAlpha
used	VBN	VP	O 723 727	[6]	[4]	LOWERCASE	allAlpha
as	IN	OTHER	O 728 730	[7]	[2]	LOWERCASE	allAlpha
an	DT	OTHER	O 731 733	[8]	[2]	LOWERCASE	allAlpha
adjuvant	JJ	OTHER	B-KP 734 742	[9]	[8]	LOWERCASE	allAlpha
for	IN	PP	O 743 746	[10]	[3]	LOWERCASE	allAlpha
infectious	JJ	NP	B-KP 747 757	[11]	[10]	LOWERCASE	allAlpha
disease	NN	NP	I-KP 758 765	[12]	[7]	LOWERCASE	allAlpha
vaccination	NN	NP	I-KP 766 777	[13]	[11]	LOWERCASE	allAlpha
[25,26]	CD	OTHER	O 778 785	[14]	[7]	LOWERCASE	ContainSymbol
and	CC	OTHER	O 786 789	[15]	[3]	LOWERCASE	allAlpha
in	IN	OTHER	O 790 792	[16]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 793 796	[17]	[3]	LOWERCASE	allAlpha
development	NN	NP	I-KP 797 808	[18]	[11]	LOWERCASE	allAlpha
of	IN	PP	I-KP 809 811	[19]	[2]	LOWERCASE	allAlpha
cancer	NN	NP	I-KP 812 818	[20]	[6]	LOWERCASE	allAlpha
therapy	NN	NP	I-KP 819 826	[21]	[7]	LOWERCASE	allAlpha
[27].	CD	OTHER	O 827 831	[22]	[5]	LOWERCASE	ContainSymbol

In	IN	OTHER	O 833 835	[1]	[2]	CAPITALIZED	allAlpha
a	DT	OTHER	O 836 837	[2]	[1]	LOWERCASE	allAlpha
mouse	NN	NP	B-KP 838 843	[3]	[5]	LOWERCASE	allAlpha
model,	NN	NP	I-KP 844 849	[4]	[6]	LOWERCASE	ContainSymbol
CpG	NN	NP	B-KP 851 854	[5]	[3]	CAPITALIZED	allAlpha
has	VBZ	VP	O 855 858	[6]	[3]	LOWERCASE	allAlpha
also	RB	OTHER	O 859 863	[7]	[4]	LOWERCASE	allAlpha
been	VBN	VP	O 864 868	[8]	[4]	LOWERCASE	allAlpha
shown	VBN	VP	O 869 874	[9]	[5]	LOWERCASE	allAlpha
to	TO	OTHER	O 875 877	[10]	[2]	LOWERCASE	allAlpha
induce	VB	VP	B-KP 878 884	[11]	[6]	LOWERCASE	allAlpha
T	NN	NP	I-KP 885 886	[12]	[1]	CAPITALIZED	allAlpha
helper	NN	NP	I-KP 887 893	[13]	[6]	LOWERCASE	allAlpha
1	CD	OTHER	I-KP 894 895	[14]	[1]	LOWERCASE	ContainSymbol
(Th1)	NN	NP	O 896 901	[15]	[5]	LOWERCASE	ContainSymbol
immune	JJ	NP	O 902 908	[16]	[6]	LOWERCASE	allAlpha
responses,	NN	NP	O 909 918	[17]	[10]	LOWERCASE	ContainSymbol
which	WDT	OTHER	O 920 925	[18]	[5]	LOWERCASE	allAlpha
are	VBP	VP	O 926 929	[19]	[3]	LOWERCASE	allAlpha
characterized	VBN	VP	O 930 943	[20]	[13]	LOWERCASE	allAlpha
by	IN	OTHER	O 944 946	[21]	[2]	LOWERCASE	allAlpha
the	DT	OTHER	O 947 950	[22]	[3]	LOWERCASE	allAlpha
production	NN	NP	B-KP 951 961	[23]	[10]	LOWERCASE	allAlpha
of	IN	PP	I-KP 962 964	[24]	[2]	LOWERCASE	allAlpha
IFN-γ	NN	NP	I-KP 965 970	[25]	[5]	CAPITALIZED	ContainSymbol
and	CC	OTHER	I-KP 971 974	[26]	[3]	LOWERCASE	allAlpha
the	DT	OTHER	I-KP 975 978	[27]	[3]	LOWERCASE	allAlpha
generation	NN	NP	I-KP 979 989	[28]	[10]	LOWERCASE	allAlpha
of	IN	PP	I-KP 990 992	[29]	[2]	LOWERCASE	allAlpha
IgG2a	FW	OTHER	I-KP 993 998	[30]	[5]	CAPITALIZED	ContainSymbol
[28,29].	FW	OTHER	O 999 1006	[31]	[8]	LOWERCASE	ContainSymbol

Moreover,	VB	VP	O 1008 1016	[1]	[9]	CAPITALIZED	ContainSymbol
a	DT	OTHER	O 1018 1019	[2]	[1]	LOWERCASE	allAlpha
previous	JJ	NP	O 1020 1028	[3]	[8]	LOWERCASE	allAlpha
study	NN	NP	O 1029 1034	[4]	[5]	LOWERCASE	allAlpha
had	VBD	VP	O 1035 1038	[5]	[3]	LOWERCASE	allAlpha
demonstrated	VBN	VP	O 1039 1051	[6]	[12]	LOWERCASE	allAlpha
that	IN	PP	O 1052 1056	[7]	[4]	LOWERCASE	allAlpha
different	JJ	NP	O 1057 1066	[8]	[9]	LOWERCASE	allAlpha
liposomes	NNS	NP	B-KP 1067 1076	[9]	[9]	LOWERCASE	allAlpha
with	IN	PP	O 1077 1081	[10]	[4]	LOWERCASE	allAlpha
CpG	NN	NP	O 1082 1085	[11]	[3]	CAPITALIZED	allAlpha
ODN	NN	NP	O 1086 1089	[12]	[3]	CAPITALIZED	allAlpha
significantly	RB	OTHER	O 1090 1103	[13]	[13]	LOWERCASE	allAlpha
increased	VBD	VP	O 1104 1113	[14]	[9]	LOWERCASE	allAlpha
Th1-biased	JJ	NP	B-KP 1114 1124	[15]	[10]	CAPITALIZED	ContainSymbol
cytokines	NNS	NP	I-KP 1125 1134	[16]	[9]	LOWERCASE	allAlpha
and	CC	OTHER	O 1135 1138	[17]	[3]	LOWERCASE	allAlpha
augmented	JJ	NP	B-KP 1139 1148	[18]	[9]	LOWERCASE	allAlpha
cell	NN	NP	I-KP 1149 1153	[19]	[4]	LOWERCASE	allAlpha
mediated	JJ	NP	I-KP 1154 1162	[20]	[8]	LOWERCASE	allAlpha
immune	JJ	NP	I-KP 1163 1169	[21]	[6]	LOWERCASE	allAlpha
response	NN	NP	I-KP 1170 1178	[22]	[8]	LOWERCASE	allAlpha
[30].	NN	NP	O 1179 1183	[23]	[5]	LOWERCASE	ContainSymbol

